ArticleOsong public health and research perspectives2025
Bridging innovation and policy: comparative pathways of national vaccine development in low- and middle-income countries.
Article in Osong public health and research perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic Readiness.Vaccines · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine how national innovation and policy configurations enabled vaccine development in Brazil, Cuba, India, and Iran, and to distil lessons for low- and middle-income country (LMIC) vaccine sovereignty.
methodsNarrative review of peer-reviewed and grey literature (2020-2023), guided by a structured search and screening approach; synthesis mapped to national and sectoral innovation system perspectives and technology readiness levels.
resultsCuba and Iran leveraged mission-oriented public research and development (R&D) and domestic platforms; India combined indigenous R&D with large-scale licensed manufacturing; Brazil's scientific capacity was constrained by fragmented governance and supply-chain dependence. Adaptive regulation (e.g., emergency use authorization/conditional approvals), targeted technology transfer, and South-South partnerships accelerated progress but raised longer-term questions about intellectual property (IP) control and economic sustainability.
conclusionInstitutional coherence, strategic IP management, and regional manufacturing alliances are as critical as scientific capacity for LMIC vaccine self-reliance. Policy priorities include pre-negotiated tech-transfer frameworks, regulatory preparedness, and investment in public R&D linked to distributed manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.